The purpose of this guidance is to identify the types of decision support software functionalities that: (1) do not meet the definition of a device as amended by the Cures Act; (2) may meet the definition of a device but for which FDA does not intend to enforce compliance with applicable requirements of the FD&C Act, including, but not limited to, premarket clearance and premarket approval requirements; and (3) FDA intends to focus its regulatory oversight on.
Artigos recentes
- Q&A ON TRANSITIONAL PROVISIONS FOR PRODUCTS WITHOUT AN INTENDED MEDICAL PURPOSE COVERED BY ANNEX XVI OF THE MDR.
- European Commission Newsletter on medical devices | September 2023
- Good clinical practice (GCP) inspection procedures : ANNEX III TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE CHMP: COMPUTER SYSTEMS
- EUDAMED Release notes Production v 2.12 September 2023.
- Regulatory Considerations for Prescription Drug Use-Related Software SEPTEMBER 2023
- EUDAMED GUIDELINE: Guidelines on Data Exchange with EUDAMED Production v 2.12 September
- INFARMED Esclarecimentos: Medicamentos essenciais de natureza crítica
- Labeling for Biosimilar and Interchangeable Biosimilar Products